William Glatt
Internal Medicine · Burlingame, CANPI 1992806319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $847 and has fallen 93.8% since, to $53 in 2023.
Across 148 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$436
- Sunovion Pharmaceuticals Inc.$203
- Collegium Pharmaceutical, Inc.$181
- Pfizer$149
- Teva Pharmaceuticals USA, Inc.$148
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$144
- plus $1K from 24 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$2,57999%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $436 |
| Sunovion Pharmaceuticals Inc. | 21 | $203 |
| Collegium Pharmaceutical, Inc. | 10 | $181 |
| Pfizer | 5 | $149 |
| Teva Pharmaceuticals USA, Inc. | 7 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $144 |
| Lilly USA, LLC | 8 | $143 |
| Amgen | 4 | $123 |
| Johnson & Johnson | 6 | $116 |
| Boehringer Ingelheim | 6 | $114 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Alkermes, Inc. | 4 | $91 |
| AstraZeneca | 4 | $66 |
| Novartis | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 2 | $54 |
| Lundbeck LLC | 2 | $48 |
| Indivior Inc. | 3 | $48 |
| Novo Nordisk | 2 | $44 |
| Hikma Pharmaceuticals USA | 2 | $43 |
| Merck | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| Orexo US, Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Bayer | 1 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Kaleo, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
How this compares
$2,600 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Burlingame
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.